Richard Scalzo
Vermögen: 904 151 $ am 31.07.2026
Vermögen: 904 151 $ am 31.07.2026
Richard William Scalzo is Chief Financial Officer at Crescent Biopharma, Inc. since 2025.
Formerly, Mr. Scalzo was Controller at Dyne Therapeutics, Inc. from 2019 to 2020, Chief Accounting Officer at Kaleido Biosciences, Inc. in 2019, Controller at X4 Pharmaceuticals, Inc. from 2016 to 2018, Controller at Astellas Institute for Regenerative Medicine in 2014.
Education includes an undergraduate degree from Boston College conferred in 2008 and an MBA from the University of Massachusetts conferred in 2016.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2026 | 24’243 ( 0.01% ) | 610 439 $ | 31.07.2026 | |
0.05% | 22.06.2026 | 20’298 ( 0.05% ) | 293 712 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|
| Unternehmen | Position | Ende |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 29.11.2019 |
| X4 PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01.08.2018 |
| OCATA THERAPEUTICS INC | Comptroller/Controller/Auditor | 01.09.2014 |
| DYNE THERAPEUTICS, INC. | Finanzdirektor/CFO | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Institute for Regenerative Medicine
Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine | Health Technology |
Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company which develops therapeutic products to systematically shape the micro biome | Health Technology |
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen